Amikacin Maturation Model As a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2013 Sep 13

PMID 24027065

Citations 15

Authors

Wei Zhao

Valerie Biran

Evelyne Jacqz-Aigrain

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Amikacin clearance has recently been proposed as a marker of renal maturation in neonates. However, the predictive value of this marker is still unknown. The objective of the present exploratory study was to evaluate the predictive performance of renal maturation model derived from amikacin to predict the glomerular filtration rate (GFR) and vancomycin clearance in neonates.

Methods: The GFR and vancomycin clearance in neonates were predicted using a maturation model derived from amikacin via estimation and simulation in a cohort of 116 neonates using non-linear mixed-effects modeling NONMEM® software.

Results: Our results demonstrate good correlations between predicted and observed GFR and vancomycin clearance in neonates. The square of the correlation coefficient, and means of the prediction error (2.5th-97.5th percentiles) and absolute prediction error (2.5th-97.5th percentiles) are 0.96, 1.2 % (-39.7 to 30.0 %) and 12.3 % (0.4-39.7 %), respectively, for GFR, and 0.97, -11.3 % (-38.2 to 15.4 %) and 14.0 % (0.5-38.2 %), respectively, for vancomycin. The prediction error is not significantly correlated with age.

Conclusion: An amikacin maturation model can precisely reflect maturation of glomerular filtration and thus predict the dosage regimens of other renally excreted drugs by glomerular filtration in neonates.

Citing Articles

Recent advances in the ontogeny of drug disposition.

Chapron B, Chapron A, Leeder J Br J Clin Pharmacol. 2021; 88(10):4267-4284.

PMID: 33733546 PMC: 8986831. DOI: 10.1111/bcp.14821.

Unraveling the Contribution of Fluid Therapy to the Development of Augmented Renal Clearance in a Piglet Model.

Dhondt L, Croubels S, De Paepe P, Goethals K, De Cock P, Devreese M Front Pharmacol. 2021; 11:607101.

PMID: 33574754 PMC: 7870502. DOI: 10.3389/fphar.2020.607101.

Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible.

DAgate S, Musuamba F, Della Pasqua O Front Pharmacol. 2020; 11:521933.

PMID: 33117151 PMC: 7549385. DOI: 10.3389/fphar.2020.521933.

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children.

Brussee J, Krekels E, Calvier E, Palic S, Rostami-Hodjegan A, Danhof M AAPS J. 2019; 21(5):81.

PMID: 31250333 PMC: 6597607. DOI: 10.1208/s12248-019-0351-9.

Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen.

Cristea S, Allegaert K, Falcao A, Falcao F, Silva R, Smits A Antimicrob Agents Chemother. 2019; 63(8).

PMID: 31182538 PMC: 6658745. DOI: 10.1128/AAC.00853-19.

References

Anderson B, Holford N . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2007; 48:303-32. DOI: 10.1146/annurev.pharmtox.48.113006.094708. View

Brendel K, Comets E, Laffont C, Laveille C, Mentre F . Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006; 23(9):2036-49. PMC: 2124466. DOI: 10.1007/s11095-006-9067-5. View

Golper T, Noonan H, Elzinga L, Gilbert D, Brummett R, Anderson J . Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988; 43(5):565-70. DOI: 10.1038/clpt.1988.74. View

Rhodin M, Anderson B, Peters A, Coulthard M, Wilkins B, Cole M . Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2008; 24(1):67-76. DOI: 10.1007/s00467-008-0997-5. View

Solhaug M, Bolger P, Jose P . The developing kidney and environmental toxins. Pediatrics. 2004; 113(4 Suppl):1084-91. View

Cella M, Knibbe C, Danhof M, Della Pasqua O . What is the right dose for children?. Br J Clin Pharmacol. 2010; 70(4):597-603. PMC: 2950994. DOI: 10.1111/j.1365-2125.2009.03591.x. View

de Cock R, Allegaert K, Schreuder M, Sherwin C, de Hoog M, van den Anker J . Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012; 51(2):105-17. DOI: 10.2165/11595640-000000000-00000. View

Blake G, Gardiner N, Gnanasegaran G, Dizdarevic S . Reference ranges for 51Cr-EDTA measurements of glomerular filtration rate in children. Nucl Med Commun. 2005; 26(11):983-7. DOI: 10.1097/01.mnm.0000179294.16339.4a. View

Swinkels D, Hendriks J, Nauta J, de Jong M . Glomerular filtration rate by single-injection inulin clearance: definition of a workable protocol for children. Ann Clin Biochem. 2000; 37 ( Pt 1):60-6. DOI: 10.1258/0004563001901533. View

10.

Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker J . Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med. 2012; 18(1):28-34. DOI: 10.1016/j.siny.2012.10.003. View

11.

Hooker A, Staatz C, Karlsson M . Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007; 24(12):2187-97. DOI: 10.1007/s11095-007-9361-x. View

12.

van den Anker J, Schwab M, Kearns G . Developmental pharmacokinetics. Handb Exp Pharmacol. 2011; 205:51-75. DOI: 10.1007/978-3-642-20195-0_2. View

13.

van den Anker J . Renal function in preterm infants. Eur J Pediatr. 1997; 156(7):583-4. View

14.

Johnson T . The problems in scaling adult drug doses to children. Arch Dis Child. 2007; 93(3):207-11. DOI: 10.1136/adc.2006.114835. View

15.

McNamara P, Alcorn J . Protein binding predictions in infants. AAPS PharmSci. 2002; 4(1):E4. PMC: 2751289. DOI: 10.1208/ps040104. View

16.

Edginton A, Schmitt W, Willmann S . Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006; 45(10):1013-34. DOI: 10.2165/00003088-200645100-00005. View

17.

Treluyer J, Merle Y, Tonnelier S, Rey E, Pons G . Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002; 46(5):1381-7. PMC: 127129. DOI: 10.1128/AAC.46.5.1381-1387.2002. View

18.

Johnson T, Rostami-Hodjegan A, Tucker G . Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006; 45(9):931-56. DOI: 10.2165/00003088-200645090-00005. View

19.

Chen N, Aleksa K, Woodland C, Rieder M, Koren G . Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2005; 21(2):160-8. DOI: 10.1007/s00467-005-2105-4. View

20.

Traynor J, Mactier R, Geddes C, Fox J . How to measure renal function in clinical practice. BMJ. 2006; 333(7571):733-7. PMC: 1592388. DOI: 10.1136/bmj.38975.390370.7C. View